Medicare Advantage plans improperly denying claims

Medicare Advantage plans—which cover about one-third of all Medicare beneficiaries—are improperly denying medical claims to patients and physicians, according to The New York Times. MA plans are incentivized to deny claims to boost profits, the report alleges.

The NY Times article builds off the report from the HHS Office of Inspector General published at the end of September that revealed as much as 75 percent of claims denials are overturned when appealed.

The report comes as Medicare Advantage plans are expanding supplemental benefits in attempts to lure older Americans to enroll. Experts anticipate that MA plan enrollment will grow quickly over the next few years.

MA plans are required to provide at least the same benefits as traditional Medicare and are contracted with private healthcare companies. MA plans can save money by keeping patients healthy and reducing utilization of higher-cost settings, but they can also save money by denying care claims. CMS has stated it has not tried to steer beneficiaries away from traditional Medicare to the MA plans.

The practice of improperly denying claims can put patients at risk, as the beneficiary may go without the service, according to the NY Times.

Read the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.